OSTEOPORE LIMITED — Board/Management Information 2021

Oct 7, 2021

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

Changes to Osteopore’s Board of Directors

8 October 2021: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenuegenerating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, today announces changes to its Board of Directors.

Osteopore wishes to advise that it has accepted the resignations of non-executive Directors, Stuart Carmichael and Geoff Pocock, effective 07 October 2021. Mr Carmichael and Mr Pocock have been valued members of the Board since June 2019, and their efforts and support were instrumental in the listing of the Company on the Australian Securities Exchange (ASX) in September 2019. Since listing, Mr Carmichael has continued to serve as a non-executive Director, while Mr Pocock served as executive Director until December 2020, whereafter he continued as a non-executive director. Both Mr Carmichael and Mr Pocock provided a valuable mix of relevant commercial, financial, and corporate governance experience to the team, providing objective counsel on strategic and operational matters to deliver a sound foundation for the Company’s future growth. The Company sincerely thanks Mr Carmichael and Mr Pocock for their contributions and wishes them the very best for the future.

Appointment of Non-Executive Independent Director

Coinciding with the resignations of Mr Carmichael and Mr Pocock, Osteopore is pleased to announce that it has secured the experienced corporate executive Daniel Ow as an independent non-executive Director. Mr Ow, an Australian qualified CPA, has over twenty years’ international experience across multiple industries, including infrastructure, resources, property and fast-moving consumer goods. Mr Ow has held several accounting and management roles with large multinational corporations and is currently Manager Financial Business Partners at Perth Airport. Along with professional experience in investor relations, he also served as Trustee Director on the Rio Tinto Staff Superannuation Fund (now merged with Equip Super).

Osteopore has an active process of Board renewal and will continue to seek to expand the depth and breadth of its director skillsets and expertise.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Carl Runde

Chief Financial Officer Osteopore Limited +61 400 118 017 carl_runde@osteopore.com

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com